Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022” report gives comprehensive clinical and non-clinical insight on the emergence and integration of controlled release technology in the drug delivery. Report highlights the ongoing development of more than 300 controlled release drugs in clinical trials and helps to analyze the existing clinical mechanism of 133 commercially available controlled release drugs in the market. The fundamentals and application of controlled release drug delivery encapsulated in the report helps to identify the various aspect of the growing controlled release drug delivery market.
“Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022” report highlights:
Controlled drug delivery technology is the one of the most rapidly advancing area in human healthcare management and already had an enormous impact on medical technology with the potential to improve health. As the goal of any drug delivery system is to provide a therapeutic amount of drug to a proper site in the body so that the desired drug concentration can be achieved promptly and then maintained, all these characteristics are provided by controlled drug delivery technologies.
It has been observed that the controlled drug delivery system offers a sustained drug action at a predetermined rate. The drug level in the body is maintained at a constant level in this system of delivery which leads to a reduction in the undesirable side effects. The controlled drug delivery system leads to localized drug action by the spatial placement of a controlled release system which is adjacent to or in the diseased tissue itself. This system offers a targeted treatment with the use of carriers or chemical derivatives in order to deliver drug to a particular target cell type. Also, the controlled drug delivery mechanism provides for a drug release system which is based on physiology or therapeutics. This implies that the amount of drugs released and the rate at which these drugs are released are highly dependent on the physiological or therapeutic demands of the body. This leads to the maintenance of safe and effective levels of blood in the body for duration which is taken by the system to deliver the drug.
The upcoming future potential for the controlled drug delivery will be outraging the conventional forms. In the future there will be several opportunities as developments are being made in order to provide the controlled drug delivery systems. With the advent of new technologies there will be a time when science would be providing the ideal drug delivery in a controlled manner. The all unmet needs of patients, physicians and payers are being promised for better treatments, controlled delivery systems with improved therapeutic profiles, increased patient compliance and enhanced bioavailability will be making the future bright for the controlled delivery products which would be able to provide successful treatment towards several diseases.
“Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022” report gives comprehensive clinical and non-clinical insight on the emergence and integration of controlled release technology in the drug delivery. Report highlights the ongoing development of more than 300 controlled release drugs in clinical trials and helps to analyze the existing clinical mechanism of 133 commercially available controlled release drugs in the market. The fundamentals and application of controlled release drug delivery encapsulated in the report helps to identify the various aspect of the growing controlled release drug delivery market.
“Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022” report highlights:
- Evolution & Fundamentals of Controlled Drug Delivery
- Mode of Action & Approaches of Controlled Drug Delivery
- Global Controlled Release Drug Market Overview
- Insight on Global Controlled Release Drug Clinical Pipeline
- Clinical Insight on 303 Controlled Release Drug in Clinical Trials
- Clinical, Patent & Technology insight of 133 Marketed Controlled Release Drugs
- Controlled Release Drug Market Future Outlook
Controlled drug delivery technology is the one of the most rapidly advancing area in human healthcare management and already had an enormous impact on medical technology with the potential to improve health. As the goal of any drug delivery system is to provide a therapeutic amount of drug to a proper site in the body so that the desired drug concentration can be achieved promptly and then maintained, all these characteristics are provided by controlled drug delivery technologies.
It has been observed that the controlled drug delivery system offers a sustained drug action at a predetermined rate. The drug level in the body is maintained at a constant level in this system of delivery which leads to a reduction in the undesirable side effects. The controlled drug delivery system leads to localized drug action by the spatial placement of a controlled release system which is adjacent to or in the diseased tissue itself. This system offers a targeted treatment with the use of carriers or chemical derivatives in order to deliver drug to a particular target cell type. Also, the controlled drug delivery mechanism provides for a drug release system which is based on physiology or therapeutics. This implies that the amount of drugs released and the rate at which these drugs are released are highly dependent on the physiological or therapeutic demands of the body. This leads to the maintenance of safe and effective levels of blood in the body for duration which is taken by the system to deliver the drug.
The upcoming future potential for the controlled drug delivery will be outraging the conventional forms. In the future there will be several opportunities as developments are being made in order to provide the controlled drug delivery systems. With the advent of new technologies there will be a time when science would be providing the ideal drug delivery in a controlled manner. The all unmet needs of patients, physicians and payers are being promised for better treatments, controlled delivery systems with improved therapeutic profiles, increased patient compliance and enhanced bioavailability will be making the future bright for the controlled delivery products which would be able to provide successful treatment towards several diseases.
1. DRUG DELIVERY: AN ADVANCING TRAJECTORY
1.1 Preface Towards Drug Delivery
1.2 Idealism of Drug Delivery System
2. INTRODUCTION TO CONTROLLED DRUG DELIVERY
2.1 Novel Drug Delivery Systems
2.2 Preamble to Controlled Drug Delivery
3. EVOLUTION OF CONTROLLED DRUG DELIVERY
3.1 First Generation
3.2 Second Generation
4. FUNDAMENTALS OF CONTROLLED DRUG DELIVERY
4.1 Prerequisites of Controlled Delivery
4.2 Rationale for Controlled Drug Delivery
5. MECHANISM OF CONTROLLED DRUG RELEASE
5.1 Diffusion Controlled
5.2 Dissolution Controlled System
5.3 Water Penetration Controlled System
5.4 Erosion Controlled System
5.5 Ion-Exchange Controlled System
6. CATALOGING OF CONTROLLED DRUG DELIVERY
6.1 Classification Based Over Delivery Systems
6.2 Classification Based Over Technicality
6.3 Classification Based Over Routes
7. APPROACHES FOR CONTROLLED DRUG DELIVERY
7.1 Polymers
7.2 Chronopharmaceutics
7.3 Nanoparticulate Delivery System
8. GLOBAL CONTROLLED RELEASE DRUG CLINICAL PIPELINE OVERVIEW
8.1 Phase
8.2 Country/Region
8.3 Mode of Action
8.4 Drug class
8.5 Indication
9. APPLICATION OF CONTROLLED DRUG DELIVERY
9.1 Diabetes
9.2 Cancer
9.3 Cardiovascular Diseases
9.4 Neurological Disorders
9.5 Infections
10. DRUG DESIGNING FOR CONTROLLED DELIVERY
10.1 Enteral Dosage Formulations
10.1.1 Solid Dosage Forms
10.1.2 Liquid Dosage Forms
10.1.3 Inhalation Dosage Forms
10.2 Parenteral Dosage Forms
10.2.1 Injectable Dosage Forms
10.2.2 Implantable Device
10.3 General Mechanisms of Drug Release
11. MARKET INCLINATIONS
11.1 Market over Routes of Administration
11.2 Market over Approaches
12. GLOBAL CONTROLLED DRUG DELIVERY MARKET DYNAMICS
12.1 Accelerative Parameters
12.2 Challenges
13. GLOBAL CONTROLLED DRUG DELIVERY MARKET FUTURE OUTLOOK
13.1 Ongoing Clinical Trials
13.2 Future Market Opportunities
14. GLOBAL CONTROLLED DRUG DELIVERY CLINICAL TRIALS BY COMPANY, INDICATION & PHASE
14.1 Unknown
14.2 Research
14.3 Preclinical
14.4 Clinical
14.5 Phase-I
14.6 Phase-I/II
14.7 Phase-II
14.8 Phase-II/III
14.9 Phase-III
14.10 Preregistration
14.11 Registered
15. MARKETED CONTROLLED RELEASE CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE
16. COMPETITIVE LANDSCAPE
16.1 Allergan
16.2 Amylin Pharmaceuticals
16.3 AstraZeneca
16.4 BioAlliance Pharma
16.5 Biogen
16.6 Collegium Pharmaceutical
16.7 Controlled Therapeutics (Ferring Pharmaceuticals)
16.8 Cosmo Pharmaceuticals
16.9 Egalet
16.10 Elan Corporation
16.11 Encore Therapeutics
16.12 Flamel Technologies
16.13 GlaxoSmithKline
16.14 Heron Therapeutics
16.15 iCeutica
16.16 Mithra Pharmaceuticals
16.17 Neurim Pharmaceuticals
16.18 Novartis
16.19 Orexigen Therapeutics
16.20 Otsuka Pharmaceutical
16.21 Pfizer
16.22 Purdue Pharma
16.23 Syntex Pharmaceuticals International
16.24 Takeda
16.25 Zealand Pharma
1.1 Preface Towards Drug Delivery
1.2 Idealism of Drug Delivery System
2. INTRODUCTION TO CONTROLLED DRUG DELIVERY
2.1 Novel Drug Delivery Systems
2.2 Preamble to Controlled Drug Delivery
3. EVOLUTION OF CONTROLLED DRUG DELIVERY
3.1 First Generation
3.2 Second Generation
4. FUNDAMENTALS OF CONTROLLED DRUG DELIVERY
4.1 Prerequisites of Controlled Delivery
4.2 Rationale for Controlled Drug Delivery
5. MECHANISM OF CONTROLLED DRUG RELEASE
5.1 Diffusion Controlled
5.2 Dissolution Controlled System
5.3 Water Penetration Controlled System
5.4 Erosion Controlled System
5.5 Ion-Exchange Controlled System
6. CATALOGING OF CONTROLLED DRUG DELIVERY
6.1 Classification Based Over Delivery Systems
6.2 Classification Based Over Technicality
6.3 Classification Based Over Routes
7. APPROACHES FOR CONTROLLED DRUG DELIVERY
7.1 Polymers
7.2 Chronopharmaceutics
7.3 Nanoparticulate Delivery System
8. GLOBAL CONTROLLED RELEASE DRUG CLINICAL PIPELINE OVERVIEW
8.1 Phase
8.2 Country/Region
8.3 Mode of Action
8.4 Drug class
8.5 Indication
9. APPLICATION OF CONTROLLED DRUG DELIVERY
9.1 Diabetes
9.2 Cancer
9.3 Cardiovascular Diseases
9.4 Neurological Disorders
9.5 Infections
10. DRUG DESIGNING FOR CONTROLLED DELIVERY
10.1 Enteral Dosage Formulations
10.1.1 Solid Dosage Forms
10.1.2 Liquid Dosage Forms
10.1.3 Inhalation Dosage Forms
10.2 Parenteral Dosage Forms
10.2.1 Injectable Dosage Forms
10.2.2 Implantable Device
10.3 General Mechanisms of Drug Release
11. MARKET INCLINATIONS
11.1 Market over Routes of Administration
11.2 Market over Approaches
12. GLOBAL CONTROLLED DRUG DELIVERY MARKET DYNAMICS
12.1 Accelerative Parameters
12.2 Challenges
13. GLOBAL CONTROLLED DRUG DELIVERY MARKET FUTURE OUTLOOK
13.1 Ongoing Clinical Trials
13.2 Future Market Opportunities
14. GLOBAL CONTROLLED DRUG DELIVERY CLINICAL TRIALS BY COMPANY, INDICATION & PHASE
14.1 Unknown
14.2 Research
14.3 Preclinical
14.4 Clinical
14.5 Phase-I
14.6 Phase-I/II
14.7 Phase-II
14.8 Phase-II/III
14.9 Phase-III
14.10 Preregistration
14.11 Registered
15. MARKETED CONTROLLED RELEASE CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE
16. COMPETITIVE LANDSCAPE
16.1 Allergan
16.2 Amylin Pharmaceuticals
16.3 AstraZeneca
16.4 BioAlliance Pharma
16.5 Biogen
16.6 Collegium Pharmaceutical
16.7 Controlled Therapeutics (Ferring Pharmaceuticals)
16.8 Cosmo Pharmaceuticals
16.9 Egalet
16.10 Elan Corporation
16.11 Encore Therapeutics
16.12 Flamel Technologies
16.13 GlaxoSmithKline
16.14 Heron Therapeutics
16.15 iCeutica
16.16 Mithra Pharmaceuticals
16.17 Neurim Pharmaceuticals
16.18 Novartis
16.19 Orexigen Therapeutics
16.20 Otsuka Pharmaceutical
16.21 Pfizer
16.22 Purdue Pharma
16.23 Syntex Pharmaceuticals International
16.24 Takeda
16.25 Zealand Pharma
LIST OF FIGURES
Figure 1-1: Characteristics of an Ideal drug Delivery System
Figure 2-1: Limitations of the Conventional Drug Delivery Systems
Figure 2-2: Diversification of the Novel Drug Delivery Platforms
Figure 3-1: History of Drug Delivery Technology from First Generation till Third Generation
Figure 3-2: Barriers to be Overcome by the Third Generation Drug Delivery System
Figure 4-1: Demonstration of the Targeted & Non-Targeted Drug Delivery
Figure 4-2: Controlled Drug Release is by Zero Order Mechanism
Figure 5-1: Differentiation of the Two Forms of the Diffusion Controlled Mechanisms
Figure 5-2: Mechanism of Encapsulation Dissolution Controlled System
Figure 5-3: Osmotic Release of the Drug Delivery with the Controlled Mechanism
Figure 5-4: Illustration of Erosion Mechanisms Found in Matrix Systems
Figure 6-1: Plasma Concentration v/s Time Profile in Conventional & Controlled Release
Figure 6-2: Comparison of Varied Modified Drug Release Systems
Figure 6-3: Illustration of Mechanism of Pulsatile Drug Release in Pulsincap
Figure 6-4: Classification Based Over the Technicality Erudition
Figure 6-5: Structural Differentiation among Varied Classified Drug Delivery Systems
Figure 6-6: Classification Based over the Route of Administration
Figure 7-1: Categorization of Polymeric Controlled Drug Delivery Devices
Figure 7-2: Varied Nanostructures Available for the Nanoparticulate Delivery System
Figure 8-1: Global - Controlled Release Drug Clinical Pipeline by Phase (%), 2017 till 2022
Figure 8-2: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 8-3: Global - Controlled Release Drug Clinical Pipeline by Phase (%),2017 till 2022
Figure 8-4: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 8-5: Global - Controlled Release Drug Clinical Pipeline by Country/Region (Number),2017 till 2022
Figure 8-6: Global - Controlled Release Clinical Drug Pipeline by Mode of Action (Number), 2017 till 2022
Figure 8-7: Global - Controlled Release Drug Clinical Pipeline by Drug Class (Number), 2017 till 2022
Figure 8-8: Global - Controlled Release Drug Clinical Pipeline by indication (Number), 2017 till 2022
Figure 9-1: Major Non-Invasive Administrative Routes of Insulin Delivery
Figure 9-2: Layout of the Controlled Drug Delivery Approaches in Cancer Therapeutics
Figure 9-3: Controlled Drug Delivery Approaches used to Deliver Drugs to CNS
Figure 10-1: Dosage Formulations for the Controlled Drug Delivery
Figure 10-2: Mechanism of the Controlled Drug Release of the Solid Dosage Forms
Figure 10-3: Representation of Categories of Liquid Dosage Form
Figure 10-4: Mechanism of Controlled Delivery of Parenteral Dosage Forms
Figure 10-5: General Forms of Oral Controlled Release System Mechanism
Figure 10-6: Schematic Diffusion Controlled Drug Release from Inert Matrices
Figure 10-7: Demonstration of the Osmotic Pump Drug Release Mechanism
Figure 11-1: Drug Delivery Share by Route of Administration, 2016
Figure 11-2: Global - Oral Drug Delivery Administration Market (US$ Billion), 2016 & 2022
Figure 11-3: Global - Injectable Drug Delivery Systems Market (US$ Billion), 2016 & 2022
Figure 11-4: Global - Implantable Device Market (US$ Billion), 2016 & 2022
Figure 11-5: Global - Topical Drug Delivery System Market (US$ Billions), 2016 & 2022
Figure 11-6: Global - Biodegradable Polymer Market (US$ Billions), 2016 & 2022
Figure 11-7: Global - Smart Polymers Market (US$ Billion), 2016 & 2022
Figure 11-8: Global - Nanomedicine Market (US$ Billion), 2016-2022
Figure 12-1: Accelerative Parameters of Controlled Drug Delivery Systems
Figure 12-2: Major Challenges Faced by Controlled Drug Delivery System
Figure 13-1: Illustration of Clinical Trials in Varied Segments for Controlled Drug Delivery
COMPANIES MENTIONED
Allergan
Amylin Pharmaceuticals
AstraZeneca
BioAlliance Pharma
Biogen
Collegium Pharmaceutical
Controlled Therapeutics (Ferring Pharmaceuticals)
Cosmo Pharmaceuticals
Egalet
Elan Corporation
Encore Therapeutics
Flamel Technologies
GlaxoSmithKline
Heron Therapeutics
iCeutica
Mithra Pharmaceuticals
Neurim Pharmaceuticals
Novartis
Orexigen Therapeutics
Otsuka Pharmaceutical
Pfizer
Purdue Pharma
Syntex Pharmaceuticals International
Takeda
Zealand Pharma
Figure 1-1: Characteristics of an Ideal drug Delivery System
Figure 2-1: Limitations of the Conventional Drug Delivery Systems
Figure 2-2: Diversification of the Novel Drug Delivery Platforms
Figure 3-1: History of Drug Delivery Technology from First Generation till Third Generation
Figure 3-2: Barriers to be Overcome by the Third Generation Drug Delivery System
Figure 4-1: Demonstration of the Targeted & Non-Targeted Drug Delivery
Figure 4-2: Controlled Drug Release is by Zero Order Mechanism
Figure 5-1: Differentiation of the Two Forms of the Diffusion Controlled Mechanisms
Figure 5-2: Mechanism of Encapsulation Dissolution Controlled System
Figure 5-3: Osmotic Release of the Drug Delivery with the Controlled Mechanism
Figure 5-4: Illustration of Erosion Mechanisms Found in Matrix Systems
Figure 6-1: Plasma Concentration v/s Time Profile in Conventional & Controlled Release
Figure 6-2: Comparison of Varied Modified Drug Release Systems
Figure 6-3: Illustration of Mechanism of Pulsatile Drug Release in Pulsincap
Figure 6-4: Classification Based Over the Technicality Erudition
Figure 6-5: Structural Differentiation among Varied Classified Drug Delivery Systems
Figure 6-6: Classification Based over the Route of Administration
Figure 7-1: Categorization of Polymeric Controlled Drug Delivery Devices
Figure 7-2: Varied Nanostructures Available for the Nanoparticulate Delivery System
Figure 8-1: Global - Controlled Release Drug Clinical Pipeline by Phase (%), 2017 till 2022
Figure 8-2: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 8-3: Global - Controlled Release Drug Clinical Pipeline by Phase (%),2017 till 2022
Figure 8-4: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 8-5: Global - Controlled Release Drug Clinical Pipeline by Country/Region (Number),2017 till 2022
Figure 8-6: Global - Controlled Release Clinical Drug Pipeline by Mode of Action (Number), 2017 till 2022
Figure 8-7: Global - Controlled Release Drug Clinical Pipeline by Drug Class (Number), 2017 till 2022
Figure 8-8: Global - Controlled Release Drug Clinical Pipeline by indication (Number), 2017 till 2022
Figure 9-1: Major Non-Invasive Administrative Routes of Insulin Delivery
Figure 9-2: Layout of the Controlled Drug Delivery Approaches in Cancer Therapeutics
Figure 9-3: Controlled Drug Delivery Approaches used to Deliver Drugs to CNS
Figure 10-1: Dosage Formulations for the Controlled Drug Delivery
Figure 10-2: Mechanism of the Controlled Drug Release of the Solid Dosage Forms
Figure 10-3: Representation of Categories of Liquid Dosage Form
Figure 10-4: Mechanism of Controlled Delivery of Parenteral Dosage Forms
Figure 10-5: General Forms of Oral Controlled Release System Mechanism
Figure 10-6: Schematic Diffusion Controlled Drug Release from Inert Matrices
Figure 10-7: Demonstration of the Osmotic Pump Drug Release Mechanism
Figure 11-1: Drug Delivery Share by Route of Administration, 2016
Figure 11-2: Global - Oral Drug Delivery Administration Market (US$ Billion), 2016 & 2022
Figure 11-3: Global - Injectable Drug Delivery Systems Market (US$ Billion), 2016 & 2022
Figure 11-4: Global - Implantable Device Market (US$ Billion), 2016 & 2022
Figure 11-5: Global - Topical Drug Delivery System Market (US$ Billions), 2016 & 2022
Figure 11-6: Global - Biodegradable Polymer Market (US$ Billions), 2016 & 2022
Figure 11-7: Global - Smart Polymers Market (US$ Billion), 2016 & 2022
Figure 11-8: Global - Nanomedicine Market (US$ Billion), 2016-2022
Figure 12-1: Accelerative Parameters of Controlled Drug Delivery Systems
Figure 12-2: Major Challenges Faced by Controlled Drug Delivery System
Figure 13-1: Illustration of Clinical Trials in Varied Segments for Controlled Drug Delivery
COMPANIES MENTIONED
Allergan
Amylin Pharmaceuticals
AstraZeneca
BioAlliance Pharma
Biogen
Collegium Pharmaceutical
Controlled Therapeutics (Ferring Pharmaceuticals)
Cosmo Pharmaceuticals
Egalet
Elan Corporation
Encore Therapeutics
Flamel Technologies
GlaxoSmithKline
Heron Therapeutics
iCeutica
Mithra Pharmaceuticals
Neurim Pharmaceuticals
Novartis
Orexigen Therapeutics
Otsuka Pharmaceutical
Pfizer
Purdue Pharma
Syntex Pharmaceuticals International
Takeda
Zealand Pharma
